S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
66,000% upside on tiny biotech? (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
Save $300 on MarketBeat All Access (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
Save $300 on MarketBeat All Access (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
KB Home Price Weakness is a Signal to Buy this Cash Machine
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
66,000% upside on tiny biotech? (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
Save $300 on MarketBeat All Access (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
Save $300 on MarketBeat All Access (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
KB Home Price Weakness is a Signal to Buy this Cash Machine
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
66,000% upside on tiny biotech? (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
Save $300 on MarketBeat All Access (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
Save $300 on MarketBeat All Access (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
KB Home Price Weakness is a Signal to Buy this Cash Machine
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
66,000% upside on tiny biotech? (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
Save $300 on MarketBeat All Access (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
Save $300 on MarketBeat All Access (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
KB Home Price Weakness is a Signal to Buy this Cash Machine
NASDAQ:AKTX

Akari Therapeutics (AKTX) Stock Forecast, Price & News

$3.60
+0.12 (+3.45%)
(As of 09/22/2023 ET)
Compare
Today's Range
$3.46
$3.62
50-Day Range
$3.10
$5.35
52-Week Range
$2.81
$13.40
Volume
10,001 shs
Average Volume
16,295 shs
Market Capitalization
$13.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.00

Akari Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,427.8% Upside
$55.00 Price Target
Short Interest
Healthy
0.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.92mentions of Akari Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

384th out of 967 stocks

Pharmaceutical Preparations Industry

161st out of 443 stocks


AKTX stock logo

About Akari Therapeutics (NASDAQ:AKTX) Stock

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

AKTX Price History

AKTX Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
He's Giving Away His Ultimate Dividend Package FOR FREE!
Marc Lichtenfeld, Author of Get Rich with Dividends, is giving away his Ultimate Dividend Package, Including Details on His #1 Dividend Stock... the Safest 8% Dividend in the World... the Top Three "Extreme Dividend" Stocks... and Much, Much More. For Free.
British pharma opens U.S. headquarters in Boston
Akari Therapeutics, Plc Announces ADS Ratio Change
See More Headlines
Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKTX Company Calendar

Last Earnings
3/31/2020
Today
9/22/2023
Next Earnings (Estimated)
9/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKTX
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$55.00
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+1,427.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.48 per share

Miscellaneous

Free Float
1,422,000
Market Cap
$13.39 million
Optionable
Not Optionable
Beta
1.40
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Ms. Rachelle Suzanne Jacques (Age 52)
    Pres, CEO & Director
    Comp: $1.38M
  • Ms. Wendy F. DiCicco CPA (Age 56)
    CPA, Interim Chief Financial Officer
  • Ms. Melissa Bradford-Klug (Age 53)
    Chief Operating Officer
  • Dr. Miles Nunn (Age 54)
    Chief Scientific Officer
  • Dr. John F. Neylan III (Age 70)
    M.D., Exec. VP & Chief Medical Officer
  • Ms. Beth-Anne Lang
    Sr. VP of Regulatory Affairs
  • Annie Mack
    Financial Controller













AKTX Stock - Frequently Asked Questions

Should I buy or sell Akari Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKTX shares.
View AKTX analyst ratings
or view top-rated stocks.

What is Akari Therapeutics' stock price forecast for 2023?

2 equities research analysts have issued 12-month price objectives for Akari Therapeutics' shares. Their AKTX share price forecasts range from $30.00 to $80.00. On average, they expect the company's stock price to reach $55.00 in the next twelve months. This suggests a possible upside of 1,427.8% from the stock's current price.
View analysts price targets for AKTX
or view top-rated stocks among Wall Street analysts.

How have AKTX shares performed in 2023?

Akari Therapeutics' stock was trading at $9.3980 on January 1st, 2023. Since then, AKTX shares have decreased by 61.7% and is now trading at $3.60.
View the best growth stocks for 2023 here
.

Are investors shorting Akari Therapeutics?

Akari Therapeutics saw a decline in short interest in August. As of August 31st, there was short interest totaling 7,900 shares, a decline of 24.8% from the August 15th total of 10,500 shares. Based on an average trading volume of 30,400 shares, the short-interest ratio is presently 0.3 days. Currently, 0.2% of the company's shares are sold short.
View Akari Therapeutics' Short Interest
.

When is Akari Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, September 26th 2023.
View our AKTX earnings forecast
.

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics, Plc (NASDAQ:AKTX) released its quarterly earnings results on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) EPS for the quarter, missing the consensus estimate of ($2.80) by $5.00.

When did Akari Therapeutics' stock split?

Akari Therapeutics's stock reverse split on the morning of Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Akari Therapeutics own?
What is Akari Therapeutics' stock symbol?

Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."

Who are Akari Therapeutics' major shareholders?

Akari Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Cerity Partners LLC (0.43%).
View institutional ownership trends
.

How do I buy shares of Akari Therapeutics?

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akari Therapeutics' stock price today?

One share of AKTX stock can currently be purchased for approximately $3.60.

How much money does Akari Therapeutics make?

Akari Therapeutics (NASDAQ:AKTX) has a market capitalization of $13.39 million. The biopharmaceutical company earns $-17,750,000.00 in net income (profit) each year or ($7.00) on an earnings per share basis.

How can I contact Akari Therapeutics?

Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The official website for the company is www.akaritx.com. The biopharmaceutical company can be reached via phone at 442080040261, via email at info@akaritx.com, or via fax at 646-843-9352.

This page (NASDAQ:AKTX) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -